News from index pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

09 Oct, 2019, 17:16 BST Bulletin from Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)

An Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) ("InDex" or the "Company") took place on Wednesday, October 9, 2019 in...


05 Sep, 2019, 08:10 BST InDex Pharmaceuticals Updates Shareholders List

InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of August...


27 Aug, 2019, 06:20 BST InDex Pharmaceuticals Meets Primary Endpoint in the Phase IIb Study CONDUCT with Cobitolimod in Ulcerative Colitis

InDex Pharmaceuticals Holding AB (publ) today announced positive top line results from the dose optimisation study CONDUCT, which is evaluating...


26 Jun, 2019, 15:06 BST InDex Pharmaceuticals Gets New Patent in Europe

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the...


26 Jun, 2019, 08:51 BST InDex Pharmaceuticals Enrolls Last Patient in Phase IIb Study CONDUCT With Cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that patient enrolment was completed in the dose optimisation study CONDUCT, which is...


11 Apr, 2019, 19:12 BST InDex Pharmaceuticals Provides Status Update on the Patient Recruitment in the CONDUCT Study

InDex Pharmaceuticals Holding AB (publ) today announced that 197 patients, of the total 215 planned, have been enrolled to date in the CONDUCT study...


20 Feb, 2019, 07:17 GMT InDex Pharmaceuticals Holding AB (publ) Year end Report 2018

STOCKHOLM, Feb. 20, 2019 /PRNewswire/ - Period October – December 2018 Revenues amounted to SEK 0.6 (0.0) million Operating result amounted to SEK...


19 Nov, 2018, 07:23 GMT InDex Pharmaceuticals Holding AB (publ) Interim Report January - September 2018

Period July – September 2018 Revenues amounted to SEK 0.0 (0.0) million Operating result amounted to SEK –15.1 (–13.3) million Result after tax...


23 Oct, 2018, 21:25 BST InDex Pharmaceuticals Carries Out a Directed Share Issue of Approximately SEK 37.5 Million

The board of directors of InDex Pharmaceuticals Holding AB (publ) (the "Company" or "InDex") has, with support from the authorization granted by the...


19 Oct, 2018, 07:38 BST InDex Pharmaceuticals Publishes Post-hoc Analysis of the COLLECT Study

InDex Pharmaceuticals Holding AB (publ) today announced the publication of a post-hoc analysis of COLLECT study data. COLLECT was a clinical study of ...


09 Aug, 2018, 19:54 BST InDex Pharmaceuticals Updates Timeline for Top Line Results from the CONDUCT Study to First Half of 2019

InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the...


31 May, 2018, 07:56 BST InDex Pharmaceuticals Will Participate in the Digestive Disease Week (DDW)

InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the...


04 May, 2018, 07:26 BST InDex Pharmaceuticals Develops Oral Formulation of Cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that it has developed a novel formulation of its lead drug candidate cobitolimod for oral...


12 Apr, 2018, 10:58 BST InDex Pharmaceuticals Announces the Agenda for its Capital Markets Day in Stockholm on April 25, 2018

InDex Pharmaceuticals Holding AB (publ) ("InDex") today announced the agenda for its Capital Markets Day that will take place in Stockholm on...


28 Mar, 2018, 14:18 BST InDex Pharmaceuticals gets New Patent in Japan

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the...


26 Feb, 2018, 07:49 GMT InDex Pharmaceuticals Holding AB (publ) Year end Report 2017

eriod October – December 2017 Revenues amounted to SEK 0.0 (0.3) million Operating result amounted to SEK –22.6 (–16.4) million Result after tax...


13 Feb, 2018, 07:14 GMT InDex Pharmaceuticals Presents Mechanism of Action Data for Cobitolimod at the ECCO Congress

InDex Pharmaceuticals Holding AB (publ) today announced that the recently reported new mechanism of action data for the drug candidate cobitolimod...


01 Dec, 2017, 07:36 GMT InDex Pharmaceuticals Reports New Mechanism of Action Data for Cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced new scientific data on the mechanism of action of cobitolimod, the company's lead drug...


17 Nov, 2017, 07:33 GMT InDex Pharmaceuticals Holding AB (publ) Interim Report January - September 2017

eriod July – September 2017 Revenues amounted to SEK 0.0 (0.0) million Operating result amounted to SEK –13.3 (–6.6) million Result after tax...


12 Oct, 2017, 07:39 BST InDex Pharmaceuticals Gets New Patent in the U.S.

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the...


13 Sep, 2017, 07:44 BST InDex Pharmaceuticals Gets New Patent Granted in Japan

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the...


09 Aug, 2017, 16:09 BST InDex Pharmaceuticals Receives Orphan-drug Designation for Pediatric Ulcerative Colitis in the US

InDex Pharmaceuticals Holding AB (publ) today announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for the...


06 Jul, 2017, 07:29 BST InDex Pharmaceuticals Gets New Patent Granted in Europe

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the...


21 Jun, 2017, 13:13 BST InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT – a phase IIb dose...


05 May, 2017, 07:12 BST InDex Pharmaceuticals Will Participate in the Digestive Disease Week (DDW)

InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the...